The biology and management of bone metastases (Q33757655)

29 July 2017

1 reference

title

The biology and management of bone metastases (English)

1 reference

29 July 2017

Plunkett TA

1 reference

29 July 2017

Rubens RD

series ordinal

1 reference

29 July 2017

publication date

1 June 1999

1 reference

Critical Reviews in Oncology Hematology

29 July 2017

published in

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

89-96

1 reference

Bone and cancer: pathophysiology and treatment of metastases

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Clinical course and prognostic factors following bone recurrence from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Bisphosphonates: mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Overview of bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Current use of bisphosphonates in oncology. International Bone and Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Use of bisphosphonates in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Palliative pamidronate treatment in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Clodronate decreases the frequency of skeletal metastases in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Monitoring of bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Metabolic effects of pamidronate in patients with metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

Markers of bone resorption in patients treated with pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900008-6

7 January 2021

10.1016/S1040-8428(99)00008-6

Identifiers

DOI

1 reference

29 July 2017

1 reference